In the BioHarmony Drug Report Database

"Preview" Icon

Ezetimibe

Zetia, Nustendi (ezetimibe) is a small molecule pharmaceutical. Ezetimibe was first approved as Zetia on 2002-10-25. It is used to treat familial combined hyperlipidemia, hypercholesterolemia, and hyperlipoproteinemia type II in the USA. It has been approved in Europe to treat dyslipidemias and hypercholesterolemia. The pharmaceutical is active against NPC1-like intracellular cholesterol transporter 1. Zetia’s patents are valid until 2025-10-30 (FDA).

 

Trade Name

 

Nustendi
 

Common Name

 

ezetimibe
 

ChEMBL ID

 

CHEMBL1138
 

Indication

 

dyslipidemias, familial combined hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia type ii
 

Drug Class

 

Antihyperlipidaemics, acyl CoA: cholesterol acyltransferase (ACAT)inhibitors

Image (chem structure or protein)

Ezetimibe structure rendering